Gilead Sciences | Capitaux D'Emprunt



Loan Capital Changement Date
AbbVie USD 60.34B 1.83B 2024-12
Agios Pharmaceuticals USD 0 0 2024-12
ALKERMES USD 0 285.82M 2024-12
Alnylam Pharmaceuticals USD 1.02B 967K 2024-12
Amgen USD 56.55B 305M 2024-12
Biogen USD 4.55B 1.4M 2024-12
BioMarin Pharmaceutical USD 595.89M 1.27M 2024-12
Bristol-Myers Squibb USD 47.6B 1.07B 2024-12
Eli Lilly USD 28.53B 518.3M 2024-12
Gilead Sciences USD 24.9B 3.46B 2024-12
GlaxoSmithKline GBP 14.64B 1.39B 2024-12
Glaxosmithkline GBP 14.64B 1.39B 2024-12
Incyte USD 33.54M 5.32M 2024-12
J&J USD 30.65B 638M 2024-12
Merck USD 34.46B 520M 2024-12
Moderna USD 39M 586M 2024-12
Neurocrine Biosciences USD 0 0 2024-12
Novartis USD 22.93B 2.41B 2024-12
Pfizer USD 57.4B 597M 2024-12
PTC Therapeutics USD 2.12B 179K 2024-12
Regeneron Pharmaceuticals USD 2.7B 720.4M 2024-12
Sanofi 12.5B 1.84B 2024-06
Sarepta Therapeutics USD 1.14B 1.16M 2024-12
United Therapeutics USD 0 0 2024-12
Vertex Pharmaceuticals USD 112.8M 1.2M 2024-12



Gilead Sciences Capitaux D'Emprunt - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Apr 2025.